Is Ligand Pharmaceuticals Incorporated (LGND) a Warren Buffett Stock?
Low Buffett fit - meets only 4/9 criteria; valuation, moat, or financial health flags risk.
4/9 criteria passed
+8 sector-quality lift. Top-quintile within its sector on 4 of 5 quality metrics. Raw pillar score 48 → lifted to 56 before grade derivation.
Capped from C to D. ROIC under 8% on both TTM and 5y average - business doesn't earn enough on capital invested; Share count growing by more than 3%/year over 5y - dilutes future per-share value; EPS dropped more than 50% at the worst point in the last 5 years - cyclical or fragile What are deal-breaker caps?
Warren Buffett's Criteria, Applied to LGND
ROIC ≥ 15%
Gross margin ≥ 40%
Owner earnings yield ≥ 5%
5y profitable
Net Debt / EBITDA ≤ 3
Revenue CAGR ≥ 8%
EPS CAGR ≥ 8%
FCF / Net income ≥ 0.8
Debt / Equity ≤ 1
How LGND Scores on Other Strategies
Live Financial Snapshot
Market cap
$4.61B
P/E (TTM)
30.4x
ROIC (TTM)
5.61%
Gross margin
98.61%
Other Warren Buffett fit reports
Frequently Asked Questions
What is LGND's Warren Buffett fit score?
Does Warren Buffett actually own LGND?
How often is this score updated?
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Warren Buffett personally owns or recommends LGND.